Kevin Rakin
Founder at ELUTIA INC.
Net worth: 8 M $ as of 2024-03-30
Profile
Kevin L.
Rakin is the founder of Helix Therapeutics, Inc. (founded in 2006), Genaissance Pharmaceuticals, Inc. (founded in 1998), HighCape Partners Management LLC (founded in 2013), Elutia, Inc. (founded in 2015), and Cybrexa, Inc. (founded in 2016).
He held various titles at Genaissance Pharmaceuticals, Inc., including President & Chief Executive Officer from 1998 to 2005.
Mr. Rakin is also the founder of HighCape Capital LP.
Mr. Rakin's current job(s) include Chairman & Chief Executive Officer at HighCape Capital Acquisition Corp.
II (since 2021), Chairman at Wellinks, Inc., Director at Cyvek, Inc. (since 2012), Independent Non-Executive Director at Nyxoah SA (since 2016), Director at Convexity Scientific, Inc. (since 2017), President & Director at Aztek Bio LLC, and Director at Quantum-Si, Inc. (since 2020).
Mr. Rakin's former job(s) include Chief Executive Officer at Shire Regenerative Medicine, Inc. (2007-2011), Chief Executive Officer at Canaan Management, Inc. (2006-2007), Chairman & Chief Executive Officer at HighCape Capital Acquisition Corp.
(2020-2021), Chairman at Oramed Pharmaceuticals, Inc. (2016-2022), Chairman at Athena Therapeutics LLC, Director at Clinical Data, Inc., Director at Vion Pharmaceuticals, Inc. (2007-2010), Director at OMRIX Biopharmaceuticals, Inc. (2007-2008), Independent Director at Histogenics Corp.
(2012-2019), Director at Cheetah Medical, Inc., Director at TELA Bio, Inc., Director at Sciona, Inc., Director at QIAGEN Marseille SA, Director at Collagen Matrix, Inc., President at Shire Regenerative Medicine, Inc. (2011-2012), and President-Regenerative Medicine at Shire Plc (2011-2012).
He was also an Advisor at Red Abbey Venture Partners LLC and a Principal at The Stevenson Group (1990-1997).
Mr. Rakin's education includes undergraduate and graduate degrees from the University of Cape Town and an MBA from Columbia Business School.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-02-29 | 2,909,924 ( 2.39% ) | 6 M $ | 2024-03-30 | |
NYXOAH SA
0.52% | 2024-03-17 | 148,500 ( 0.52% ) | 2 M $ | 2024-03-30 |
ELUTIA INC CLASS A
0.45% | 2023-12-27 | 90,807 ( 0.45% ) | 286 042 $ | 2024-03-30 |
Kevin Rakin active positions
Companies | Position | Start |
---|---|---|
ELUTIA INC. | Founder | 2015-08-05 |
NYXOAH SA | Director/Board Member | 2016-06-28 |
QUANTUM-SI INCORPORATED | Director/Board Member | 2020-06-09 |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Founder | 2015-12-31 |
Wellinks, Inc.
Wellinks, Inc. Packaged SoftwareTechnology Services Wellinks, Inc. provides wearable health technology services. It engages in improving clinical outcomes through education and creation of good habits around treatment. The company was founded by Ellen Su, Sebastian Monzon and Levi Deluke and is headquartered in New Haven, CT. | Chairman | - |
HighCape Capital Acquisition Corp. II
HighCape Capital Acquisition Corp. II Financial ConglomeratesFinance HighCape Capital Acquisition Corp. II operates as a blank check company. Its objective is effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination. The company was founded on February 9, 2021 and is headquartered in New York, NY. | Chief Executive Officer | 2021-01-31 |
CyVek, Inc.
CyVek, Inc. BiotechnologyHealth Technology CyVek, Inc. engages in the development of a novel, platform technology for measuring analytes in biological samples. It is a biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays. The firm is a versatile platform that can be quickly and easily configured for diverse applications such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings. The company offers an breadth of applications, from life science research to drug discovery, personalized medicine, diagnostics, and point-of-care testing. CyVek was founded by Per J. Hellsund, Rajiv Pandey and Marty Andrew Putnam in 2010 and is headquartered in Wallingford, CT. | Director/Board Member | 2011-12-31 |
Former positions of Kevin Rakin
Companies | Position | End |
---|---|---|
Red Abbey Venture Partners LLC
Red Abbey Venture Partners LLC Investment ManagersFinance Red Abbey Venture Partners LLC (Red Abbey Venture Partners) is a venture capital firm subsidiary of Red Abbey LLC founded in 2004 by Philip Goelet, W. Matthew Zuga, and Frank Adair Bonsal. The firm is headquartered in Baltimore, Maryland. | Consultant / Advisor | 2022-12-22 |
ORAMED PHARMACEUTICALS INC. | Chairman | 2022-06-29 |
░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Kevin Rakin
University of Cape Town | Graduate Degree |
Columbia Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
TELA BIO, INC. | Health Technology |
NYXOAH SA | Health Technology |
ORAMED PHARMACEUTICALS INC. | Health Technology |
QUANTUM-SI INCORPORATED | Technology Services |
Private companies | 21 |
---|---|
Clinical Data, Inc.
Clinical Data, Inc. Medical SpecialtiesHealth Technology Clinical Data, Inc. manufactured and distributed scientific instruments used in clinical and analytical laboratories. The company was founded in 1972 and was headquartered in Newton, MA. | Health Technology |
Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Shire Regenerative Medicine, Inc.
Shire Regenerative Medicine, Inc. BiotechnologyHealth Technology Shire Regenerative Medicine, Inc. develops and commercializes living cell therapies. It manufactures and markets dermagraft, a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body's natural healing process. The company was founded in 2004 and is headquartered in Westport, CT. | Health Technology |
Red Abbey Venture Partners LLC
Red Abbey Venture Partners LLC Investment ManagersFinance Red Abbey Venture Partners LLC (Red Abbey Venture Partners) is a venture capital firm subsidiary of Red Abbey LLC founded in 2004 by Philip Goelet, W. Matthew Zuga, and Frank Adair Bonsal. The firm is headquartered in Baltimore, Maryland. | Finance |
OMRIX Biopharmaceuticals, Inc.
OMRIX Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ. | Health Technology |
Canaan Management, Inc.
Canaan Management, Inc. Investment ManagersFinance Canaan Management, Inc. (Canaan Management) is a venture capital firm founded in 1987 by Eric A. Young. The firm is headquartered in Westport, CT. | Finance |
Cheetah Medical, Inc.
Cheetah Medical, Inc. Hospital/Nursing ManagementHealth Services Cheetah Medical, Inc. develops and markets non-invasive blood monitoring system. The firm offers cheetah sensors, staling SV and cheetah nicom devices. It provides noninvasive hemodynamic monitoring technologies which are designed for use in critical care, operating room and emergency department settings for a wide variety of patient populations. The company was founded by Hanan Keren in 2000 and is headquartered in Newton Center, MA. | Health Services |
Genaissance Pharmaceuticals, Inc.
Genaissance Pharmaceuticals, Inc. BiotechnologyHealth Technology Genaissance Pharmaceuticals, Inc. develops and uses genetic information to diagnostic and therapeutic products. The company was founded by Kevin L. Rakin and Gualberto Ruano in 1992 and is headquartered in New Haven, CT. | Health Technology |
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Histogenics Corp.
Histogenics Corp. BiotechnologyHealth Technology Histogenics Corp. engages in the development, marketing, and commercialization of restorative cell therapies. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually and in concert to treat musculoskeletal-related conditions. The company was founded on June 28, 2000 and is headquartered in Waltham, MA. | Health Technology |
CyVek, Inc.
CyVek, Inc. BiotechnologyHealth Technology CyVek, Inc. engages in the development of a novel, platform technology for measuring analytes in biological samples. It is a biotechnology company dedicated to the advancement of healthcare by empowering researchers and clinicians with a disruptive technology for performing multi-analyte immunoassays. The firm is a versatile platform that can be quickly and easily configured for diverse applications such as rapid diagnostic tests, multi-sample multi-analyte tests, or routine ELISA-like tests, for use in both research and clinical settings. The company offers an breadth of applications, from life science research to drug discovery, personalized medicine, diagnostics, and point-of-care testing. CyVek was founded by Per J. Hellsund, Rajiv Pandey and Marty Andrew Putnam in 2010 and is headquartered in Wallingford, CT. | Health Technology |
HighCape Partners Management LLC
HighCape Partners Management LLC Investment ManagersFinance HighCape Partners Management LLC (HighCape Partners) is a private equity firm founded in 2013 by Kevin Rakin and Matt Zuga. The firm headquartered in Westport, Connecticut.. | Finance |
The Stevenson Group
The Stevenson Group Other TransportationTransportation The Stevenson Group provides fulfillment and distribution services for a variety of products. It offers its services to pharmaceutical, biotechnology, medical devices, diagnostics, and healthcare services firms in the Americas and Europe. The company was founded by Stephen Steinman in 1979 and is headquartered in Fort Lee, NJ. | Transportation |
Helix Therapeutics, Inc.
Helix Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Helix Therapeutics is a seed stage company based on technology discovered in the laboratory of Peter Glazer MD/PhD and licensed on a world wide, exclusive basis from Yale University. Targeted DNA modifications can be designed to: correct mutations, leading to restoration of normal function of key gene products, alter levels of gene expression, potentially turning genes on or off, functionally disrupt molecules, such as the CCR5 receptor, which mediates HIV entry into T cells. Through the use of SBIR grants and seed funding, it will advance preclinical projects targeting the human globin gene for applications on sickle cell anemia and beta-thalassemia, the CCR5 receptor for the HIV/AIDS population, and genetic mutations responsible for the liposomal storage disease, Gaucher's. Genetic alteration of stem cells has the potential to dramatically impact the efficacy of stem cell therapy for human disease. Due to the accessibility of HSC without bone marrow transplants, the company is currently focused on blood based genetic diseases. As advances in human stem cell biology are realized, however, it is possible to envision applications in a broad array of human genetic diseases. Moreover, because the DNA modifications introduced to stem cells are stable and heritable; this technology offers the hope of curing certain genetic diseases. Its approach does not rely on viral vectors and corrects the patients own cells, eliminating potential immune reactions. This approach is classified as Cellular Therapy, which provides another level of safety to the patient. | Health Technology |
HighCape Capital Acquisition Corp. II
HighCape Capital Acquisition Corp. II Financial ConglomeratesFinance HighCape Capital Acquisition Corp. II operates as a blank check company. Its objective is effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination. The company was founded on February 9, 2021 and is headquartered in New York, NY. | Finance |
Elutia, Inc. | |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Health Technology |
HighCape Capital Acquisition Corp.
HighCape Capital Acquisition Corp. Financial ConglomeratesFinance HighCape Capital Acquisition Corp. operates as a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses for its initial business. The company was founded on June 10, 2020 and is headquartered in New York, NY. | Finance |
Collagen Matrix, Inc.
Collagen Matrix, Inc. Medical SpecialtiesHealth Technology Collagen Matrix, Inc. design and manufactures extracellular matrices for tissue and organ repair and regeneration. The firm offers collagen and mineral-based finished medical devices in the areas of orthopedic-spine surgery, neurosurgery, oral surgery, and wound care. It provides DuraMatrix, Neuroflex, NeuroMatrix, OssiMend, and the Matrix Collagen. The company was founded by Shu-Tung Li in 1997 and is headquartered in Oakland, NJ. | Health Technology |
Wellinks, Inc.
Wellinks, Inc. Packaged SoftwareTechnology Services Wellinks, Inc. provides wearable health technology services. It engages in improving clinical outcomes through education and creation of good habits around treatment. The company was founded by Ellen Su, Sebastian Monzon and Levi Deluke and is headquartered in New Haven, CT. | Technology Services |
- Stock Market
- Insiders
- Kevin Rakin